0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover4129.81%IV-32.37%PremiumMay 17, 2024Expiry Date7.18Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9167Delta0.0216Gamma--Leverage Ratio-24.4893Theta0.0000Rho0.00Eff Leverage0.0003Vega
Calliditas Therapeutics Stock Discussion
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...
📊⚡️📊
No comment yet